Literature DB >> 16868661

Immunohistochemical expression of peripheral benzodiazepine receptors in human astrocytomas and its correlation with grade of malignancy, proliferation, apoptosis and survival.

Eugene Vlodavsky1, Jean F Soustiel.   

Abstract

Peripheral benzodiazepine receptors (PBR) are widely distributed in peripheral tissues, astrocytes, and microglia of the brain. They are involved in apoptosis, proliferation, and many other processes, such as steroidogenesis in adrenal glands, male and female gonads, biological adaptation to stress, etc. It has been established that the expression of PBR in astrocytomas is higher than in the normal brain. The goal of this study was to explore the correlation of the immunohistochemical expression of PBR in astrocytomas with the grade of malignancy and rates of apoptosis, proliferation and survival. In 130 cases of astrocytomas (25 grade I, 25 grade II, 20 grade III, 60 grade IV), paraffin sections were stained immunohistochemically for PBR and MIB-1(Ki-67). TUNEL assay was used for evaluation of apoptosis. It was found that the intensity and extent of staining for PBR had a strong direct correlation with the grade of malignancy of the tumor, along with proliferative and apoptotic indices. The highest expression of PBR was in glioblastomas grade IV, especially around areas of necrosis. There was a strong negative correlation between PBR expression and survival. The results of this study may be applied in the pathological diagnosis of astrocytomas as an additional clue in establishing tumor grade; they may be used in the imaging of astrocytomas, both for diagnosis and follow-up, by the application of positron emission tomography scanning with PBR specific ligands. Targeting of PBR in high-grade gliomas may be a promising approach, achieving more specific anti-tumor effect.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16868661     DOI: 10.1007/s11060-006-9199-9

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  35 in total

Review 1.  Ultrastructural pathology of glial brain tumors revisited: a review.

Authors:  P P Liberski; R Kordek
Journal:  Ultrastruct Pathol       Date:  1997 Jan-Feb       Impact factor: 1.094

2.  Heterogeneity of apoptotic pathways and c.Jun/JNK expression in malignant gliomas.

Authors:  D Schiffer; R Ferracini; P Cavalla
Journal:  Anticancer Res       Date:  2001 Jul-Aug       Impact factor: 2.480

3.  Overexpression of the peripheral benzodiazepine receptor is a relevant prognostic factor in stage III colorectal cancer.

Authors:  Kerstin Maaser; Patricia Grabowski; Andreas P Sutter; Michael Höpfner; Hans-Dieter Foss; Harald Stein; Gerd Berger; Moshe Gavish; Martin Zeitz; Hans Scherübl
Journal:  Clin Cancer Res       Date:  2002-10       Impact factor: 12.531

4.  Assessment of the peripheral benzodiazepine receptors in human gliomas by two methods.

Authors:  N Miyazawa; E Hamel; M Diksic
Journal:  J Neurooncol       Date:  1998-05       Impact factor: 4.130

5.  Apoptosis in astrocytic neoplasms.

Authors:  R S Carroll; J Zhang; B W Chauncey; K Chantziara; M P Frosch; P M Black
Journal:  Acta Neurochir (Wien)       Date:  1997       Impact factor: 2.216

Review 6.  Peripheral benzodiazepine receptors and mitochondrial function.

Authors:  Pierre Casellas; Sylvaine Galiegue; Anthony S Basile
Journal:  Neurochem Int       Date:  2002-05       Impact factor: 3.921

7.  The peripheral-type benzodiazepine receptor and tumorigenicity: isoquinoline binding protein (IBP) antisense knockdown in the C6 glioma cell line.

Authors:  Evgeny Levin; Arumugam Premkumar; Leo Veenman; Wilfried Kugler; Svetlana Leschiner; Ilana Spanier; Gary Weisinger; Max Lakomek; Abraham Weizman; Solomon H Snyder; Gavril W Pasternak; Moshe Gavish
Journal:  Biochemistry       Date:  2005-07-26       Impact factor: 3.162

8.  Apoptosis and proliferation: correlation with p53 in astrocytic tumours.

Authors:  Chitra Sarkar; Asis Kumar Karak; Neera Nath; Mehar Chand Sharma; Ashok Kumar Mahapatra; Parthoprasad Chattopadhyay; Subrata Sinha
Journal:  J Neurooncol       Date:  2005-06       Impact factor: 4.130

9.  Apoptosis in astrocytomas with different grades of malignancy.

Authors:  D T Yew; H H Wang; D R Zheng
Journal:  Acta Neurochir (Wien)       Date:  1998       Impact factor: 2.216

10.  Prognostic significance of an apoptotic index and apoptosis/proliferation ratio for patients with high-grade astrocytomas.

Authors:  Hiroko Kuriyama; Kathleen R Lamborn; Judith R O'Fallon; N Iturria; Thomas Sebo; Paul L Schaefer; Bernd W Scheithauer; Jan C Buckner; Nagato Kuriyama; Robert B Jenkins; Mark A Israel
Journal:  Neuro Oncol       Date:  2002-07       Impact factor: 12.300

View more
  41 in total

1.  The expression of translocator protein in human thyroid cancer and its role in the response of thyroid cancer cells to oxidative stress.

Authors:  Joanna Klubo-Gwiezdzinska; Kirk Jensen; Andrew Bauer; Aneeta Patel; John Costello; Kenneth D Burman; Leonard Wartofsky; Matthew J Hardwick; Vasyl V Vasko
Journal:  J Endocrinol       Date:  2012-05-29       Impact factor: 4.286

2.  TSPO PET, tumour grading and molecular genetics in histologically verified glioma: a correlative 18F-GE-180 PET study.

Authors:  M Unterrainer; D F Fleischmann; F Vettermann; V Ruf; L Kaiser; D Nelwan; S Lindner; M Brendel; V Wenter; S Stöcklein; J Herms; V M Milenkovic; R Rupprecht; J C Tonn; C Belka; P Bartenstein; M Niyazi; N L Albert
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-09-05       Impact factor: 9.236

3.  TSPO deficiency induces mitochondrial dysfunction, leading to hypoxia, angiogenesis, and a growth-promoting metabolic shift toward glycolysis in glioblastoma.

Authors:  Yi Fu; Dongdong Wang; Huaishan Wang; Menghua Cai; Chao Li; Xue Zhang; Hui Chen; Yu Hu; Xuan Zhang; Mingyao Ying; Wei He; Jianmin Zhang
Journal:  Neuro Oncol       Date:  2020-02-20       Impact factor: 12.300

4.  TSPO PET for glioma imaging using the novel ligand 18F-GE-180: first results in patients with glioblastoma.

Authors:  Nathalie L Albert; M Unterrainer; D F Fleischmann; S Lindner; F Vettermann; A Brunegraf; L Vomacka; M Brendel; V Wenter; C Wetzel; R Rupprecht; J-C Tonn; C Belka; P Bartenstein; M Niyazi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-08-19       Impact factor: 9.236

5.  TSPO PET using 18F-GE-180: a new perspective in neurooncology?

Authors:  Karl-Josef Langen; Antje Willuweit
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-10-12       Impact factor: 9.236

6.  Multilayer photodynamic therapy for highly effective and safe cancer treatment.

Authors:  Ling Yang; Shaojuan Zhang; Xiaoxi Ling; Pin Shao; Ningyang Jia; Mingfeng Bai
Journal:  Acta Biomater       Date:  2017-03-09       Impact factor: 8.947

Review 7.  Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders.

Authors:  Rainer Rupprecht; Vassilios Papadopoulos; Gerhard Rammes; Thomas C Baghai; Jinjiang Fan; Nagaraju Akula; Ghislaine Groyer; David Adams; Michael Schumacher
Journal:  Nat Rev Drug Discov       Date:  2010-12       Impact factor: 84.694

Review 8.  New strategies to deliver anticancer drugs to brain tumors.

Authors:  Valentino Laquintana; Adriana Trapani; Nunzio Denora; Fan Wang; James M Gallo; Giuseppe Trapani
Journal:  Expert Opin Drug Deliv       Date:  2009-10       Impact factor: 6.648

9.  Expression of the translocator protein of 18 kDa by microglia, macrophages and astrocytes based on immunohistochemical localization in abnormal human brain.

Authors:  M Cosenza-Nashat; M-L Zhao; H-S Suh; J Morgan; R Natividad; S Morgello; S C Lee
Journal:  Neuropathol Appl Neurobiol       Date:  2008-12-11       Impact factor: 8.090

10.  The translocator protein (TSPO) ligand PK11195 induces apoptosis and cell cycle arrest and sensitizes to chemotherapy treatment in pre- and post-relapse neuroblastoma cell lines.

Authors:  Maria C Mendonça-Torres; Stephen S Roberts
Journal:  Cancer Biol Ther       Date:  2013-01-28       Impact factor: 4.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.